AMCo allocates, merges, makes hefty scalebacks
![drugs](https://assets.euromoneydigital.com/dims4/default/8b06c64/2147483647/strip/true/crop/200x150+0+0/resize/840x630!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F25%2F42%2F5e12d15d7d13da201d87802b0762%2Fdrugsforweb.jpg)
Amdipharm Mercury, the UK generic pharmaceuticals company also known as AMCo, has allocated a €603.2m loan that raises new money and reprices existing facilities.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: